Quality of life in patients with advanced bladder cancer treated by tumorectomy and systemic adjuvant polychemotherapy (M-VAC). Our experience in 14 cases.
Fourteen patients with advanced bladder cancer T3 to T4, N1 to N2 positive, were treated with reductive surgery (tumorectomy) and systemic adjuvant polychemotherapy (M-VAC: methotrexate 30 mg/m2, vinblastine 3 mg/m2, adriamycin 30 mg/m2 and cis-platin 70 mg/m2) in the period from December 1985 to December 1987. The aim of this combination was to preserve detrusor function in order to give tha patients a better "quality of life". After a follow-up varying from 12-24 months, complete clinical remission for 18 months was observed in 2 patients, the remainder showed an improvement of the performance status compared with those treated by conventional therapy (radical cystectomy and/or radiotherapy) but no changes in overall survival was achieved.
Valente
R
R
Marini
F
F
Signori
G B
GB
Martino
F
F
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011788:Quality of Life; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate